

In the claims:

Cancel claims 1-14.

Amend claims 15 and 16 as follows:

15. (Amended) ¹A antibody that binds to a previously unknown epitope on a preselected antigen, said antibody obtained by the method comprising:
- forming an immunocomplex by contacting the preselected antigen with a first antibody bound to a solid support, wherein the first antibody specifically binds to a preselected epitope present on the preselected antigen;
 - contacting the immunocomplex of a) with a combinatorial library of antibodies under conditions that allow binding of the second antibody to the previously unknown epitope, wherein a second antibody is obtained from screening the combinatorial library;
 - removing the second antibody of b) from the previously unknown epitope; and
 - obtaining the second antibody.

16. (Amended) The antibody of claim 15, wherein the antibody has the specificity of an antibody produced by B-cells ATCC 69522.

The following claims have been added:

17. ~~The antibody of claim 15, wherein the first antibody is an Fb or an Fab fragment.~~
18. ~~The antibody of claim 15, wherein the antigen is selected from the group consisting of a bacterial, a viral, a parasitic, a fungal, a tumor and a self antigen.~~
19. The antibody of claim 18, wherein the viral antigen is selected from the group of viruses consisting of a hepatitis B virus (HBV), a human immunodeficiency virus (HIV), an influenza A virus, an Epstein Barr virus (EBV), a herpes simplex virus (HSV), a respiratory syncytial virus (RSV), a human cytomegalovirus (HCMV), a varicella zoster virus (VZV), and a measles virus.

20. The antibody of claim 19, wherein the viral antigen is a HSV glycoprotein D.
- ~~21. The antibody of claim 15, wherein the preselected epitope is a non-neutralizing epitope.~~
22. The antibody of claim 15, wherein the previously unknown epitope is a neutralizing epitope.
23. The antibody of claim 17, further comprising sequencing a nucleic acid encoding an amino acid sequence of the second antibody.

THE JOURNAL